Linaclotide
لیناکلوتاید
🍽️ Alimentary Tract And MetabolismGuanylate cyclase-C agonist
Market / country: 🇺🇸 USA
Linzess (US)
🧮 Dose calculator
Functional bowel / irritable bowel syndrome · Regimen source: FDA Linzess · 2.1
- • On an empty stomach at least 30 min before a meal; do not crush or chew. FDA Linzess · 2.1FDA Linzess · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Under 2 years (risk of serious dehydration). FDA Linzess · 4
- ⛔ Known or suspected mechanical GI obstruction. FDA Linzess · 4
Formulations
- 72 mcg capsule — capsule 🇺🇸 USA FDA Linzess · 3
- 145 mcg capsule — capsule 🇺🇸 USA FDA Linzess · 3
- 290 mcg capsule — capsule 🇺🇸 USA FDA Linzess · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Darooyab: category C — only if benefit outweighs risk. Darooyab · G-5499/Linaclotide — مصرف در بارداری
“مصرف در بارداری لیناکلوتاید گروه C در شرايط خاص و نظارت ويژه پزشك قابل استفاده است:”
- 🤱 BreastfeedingNo specific problem stated
Label: infant exposure not expected. FDA Linzess · 8.2
“Maternal use of LINZESS is not expected to result in exposure to linaclotide or its active metabolite in breastfed infants.”
- 👶 ChildrenUse with caution
Label: contraindicated under 2 years (serious dehydration); approved for functional constipation from 2 y and IBS-C from 7 y. FDA Linzess · 4
“LINZESS is contraindicated in: Patients less than 2 years of age due to the risk of serious dehydration”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Linzess · 8.5
“In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA202811
- DailyMed (FDA label)FDA Linzess
- MedlinePlus (NIH)Linaclotide
- WHO ATC/DDDA06AX04
- Darooyab (Iran)Linaclotide
🇮🇷 Registered in Iran Darooyab · G-5499/Linaclotide
Dosage forms with Iranian generic codes, per Darooyab.
- 50833 · LINACLOTIDE 145 mcg CAPSULE · کپسول لیناکلوتاید ۱۴۵ میکروگرم
- 53263 · LINACLOTIDE 72 mcg CAPSULE · کپسول لیناکلوتاید ۷۲ میکروگرم
- 52508 · LINACLOTIDE 290 mcg CAPSULE · کپسول لیناکلوتاید ۲۹۰ میکروگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Linzess · 3FDA Linzess · 2.1FDA Linzess · 2.2FDA Linzess · 4FDA Linzess · SPL approval / marketing categoryFDA Linzess · 8.2FDA Linzess · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-5499/LinaclotideDarooyab · G-5499/Linaclotide — مصرف در بارداری
- Clinical review⚠ Unverified